Amgen beats the street and announces $425M cancer vaccine maker purchase

As the first drug maker out of the gate reporting 2010 year-end results, Amgen posted profits slightly better than Wall Street had been predicting in a year in which the company not only gained US approval of denosumab – the drug its banking its future on – but also won a second indication from the US FDA for the injectable RANK Ligand inhibitor.